H.PIO Co., Ltd. (KOSDAQ:357230)
South Korea · Delayed Price · Currency is KRW 2,605.00
+85.00 (3.37%)
At close: Apr 20, 2026
H.PIO Revenue
In the year 2025, H.PIO had annual revenue of 258.19B KRW with 6.32% growth. H.PIO had revenue of 63.48B in the quarter ending December 31, 2025, with 1.00% growth.
Revenue
258.19B
Revenue Growth
+6.32%
P/S Ratio
0.42
Revenue / Employee
3.40B
Employees
76
Market Cap
107.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 258.19B | 15.36B | 6.32% |
| Dec 31, 2024 | 242.83B | 10.80B | 4.66% |
| Dec 31, 2023 | 232.03B | 36.05B | 18.39% |
| Dec 31, 2022 | 195.98B | 36.54B | 22.92% |
| Dec 31, 2021 | 159.43B | 16.65B | 11.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 306.87B |
| Cosmax Nbt | 287.48B |
| Daehan Nupharm | 202.40B |
| HYUNDAI BIOLAND | 130.51B |
| Sinsin Pharmaceutical | 113.78B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| KOREA PHARMA | 87.60B |
| Sam-A Pharm. | 77.80B |